ASH 2021 | MRD updates in multiple myeloma at ASH 2021
Faith Davies
• 10 Dec 2021
Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone Medical Center, New York, NY, provides updates in the field of minimal residual disease (MRD) testing in multiple myeloma, including studies assessing the MRD status of patients receiving daratumumab at different points in time, as well as data linking MRD negativity to better outcomes in patients. Prof. Davies additionally highlights the need for MRD testing in the clinic, and how MRD testing can build on existing treatments such as dexamethasone and lenaliomide. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
